Abstract

Given the available data showing greater immunogenicity of bivalent vaccines adapted to Omicron (Spikevax bivalent Original/ Omicron BA.1, Comirnaty bivalent Original/ Omicron BA.1, Comirnaty bivalent Original/ Omicron BA.4-5) against sub- variants of Omicron (which are the viral forms currently circulating) and reactogenicity similar to the original vaccines, HAS has concluded that, as soon as they become available, these vaccines can be integrated into the vaccine strategy and be used preferentially to vaccines during the booster vaccination campaign scheduled for the fall, regardless of the vaccine(s) previously administered.

In the absence of data enabling the bivalent vaccines to be compared with each other, they may be used interchangeably in the context of the vaccination campaign. It should be noted, however, that for people under 30, only the Comirnaty and Comirnaty bivalent Original / Omicron BA.1 and Comirnaty bivalent Original / Omicron BA.4-5 vaccines remain recommended. HAS notes that the original monovalent vaccines Spikevax and Comirnaty can continue to be used in primary vaccination.

  • Recommendation
  • Europe
  • France
  • COVID-19